Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

A competing-risks nomogram for sarcoma-specific death following local recurrence.

Kattan MW, Heller G, Brennan MF.

Stat Med. 2003 Nov 30;22(22):3515-25.

PMID:
14601016
2.

Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system.

Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A.

Cancer. 2005 Jan 15;103(2):402-8.

3.

Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.

Kanao K, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M.

J Urol. 2009 Feb;181(2):480-5; discussion 485. doi: 10.1016/j.juro.2008.10.017. Epub 2008 Dec 19.

PMID:
19100568
4.

Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches.

Tai BC, Machin D, White I, Gebski V; EOI (The European Osteosarcoma Intergroup).

Stat Med. 2001 Mar 15;20(5):661-84.

PMID:
11241570
5.
6.

Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR.

J Urol. 2005 Apr;173(4):1126-31.

7.

Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.

Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP.

J Urol. 2006 Oct;176(4 Pt 1):1354-61; discussion 1361-2.

PMID:
16952631
8.

A nomogram predicting long-term biochemical recurrence after radical prostatectomy.

Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, Correa R, Montorsi F, Graefen M, Huland H, Klein EA, Karakiewicz PI.

Cancer. 2008 Mar 15;112(6):1254-63. doi: 10.1002/cncr.23293.

9.

Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution.

Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M, Rosai J.

Cancer. 2004 Jun 1;100(11):2448-55.

10.

A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.

Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P.

J Urol. 2005 Jan;173(1):48-51.

PMID:
15592023
11.

Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.

Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI.

J Clin Oncol. 2005 Sep 20;23(27):6533-9. Epub 2005 Aug 22.

PMID:
16116151
12.

Validation of the postoperative nomogram for 12-year sarcoma-specific mortality.

Eilber FC, Brennan MF, Eilber FR, Dry SM, Singer S, Kattan MW.

Cancer. 2004 Nov 15;101(10):2270-5.

13.

Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients.

Hupertan V, Roupret M, Poisson JF, Chretien Y, Dufour B, Thiounn N, Mejean A.

Cancer. 2006 Dec 1;107(11):2604-8.

14.

Exactitude of relative survival compared with cause-specific survival and competing risk estimations based on a clinical database of patients with colorectal carcinoma.

Stelzner S, Hellmich G, Koch R, Witzigmann H.

Dis Colon Rectum. 2009 Jul;52(7):1264-71. doi: 10.1007/DCR.0b013e3181a0dd71.

PMID:
19571703
15.

Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO.

Ataman OU, Barrett A, Filleron T, Kramar A; ESTRO-REACT Group.

Radiother Oncol. 2006 Jan;78(1):95-100. Epub 2005 Oct 26.

PMID:
16256232
16.

Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.

Roach M 3rd, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW.

J Urol. 2006 Dec;176(6 Pt 2):S16-20.

PMID:
17084158
17.

SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data.

Rosthøj S, Andersen PK, Abildstrom SZ.

Comput Methods Programs Biomed. 2004 Apr;74(1):69-75.

PMID:
14992828
18.

Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.

van den Broek GB, Rasch CR, Pameijer FA, Peter E, van den Brekel MW, Tan IB, Schornagel JH, de Bois JA, Zijp LJ, Balm AJ.

Cancer. 2004 Oct 15;101(8):1809-17. Review.

19.

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.

Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T; Cancer Registration Committee of the Japanese Urological Association.

Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.

20.

Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity.

Alektiar KM, Brennan MF, Healey JH, Singer S.

J Clin Oncol. 2008 Jul 10;26(20):3440-4. doi: 10.1200/JCO.2008.16.6249.

PMID:
18612160

Supplemental Content

Support Center